Celldex Therapeutics saw its price target raised from $70 to $88 by Leerink Partners following successful Phase III trial results for its drug barzolvolimab treating chronic spontaneous urticaria (CSU). The trials met all primary endpoints, showing lasting benefits over 24 weeks in nearly 2,000 patients. Despite this, Celldex's stock dipped slightly after halting a separate Phase 2 trial for another condition. The company plans to submit for FDA approval in 2027, marking a key step forward for the drug's market potential.
Celldex Therapeutics' recent price target increase is presented here alongside Pluang's health sector data for context. As of Sep 23, 2026 22:11 WIB, out of 100 priced health-sector US stocks on Pluang, 26 rose while 72 fell. Among notable stocks, RXRX traded at USD 3.87 with a 4.44% decline and a typical hold time of 22 days, contrasting with TXG at USD 77.68 down 3.74% but held for 94 days, and CYTK at USD 65.09 down 3.70% with a 18-day hold time. Pluang order activity showed a strong sell bias for RXRX (98% Sell) and a more balanced activity for TXG and CYTK.
Jefferies analysts set a new price target of $435 for General Electric Aerospace, implying a 35% upside from its current price of around $321. GE Aerospace's strong position is supported by a $170 billion commercial services backlog and 80,000 aircra...
BNP Paribas lowered its price target for PepsiCo from $183 to $161 on September 23, 2026, due to ongoing demand challenges in North America. Despite the cut, the firm maintained an Outperform rating, indicating confidence in the stock's potential. Th...
Ero Copper, a major copper producer, shows stock volatility between $16.88 and $40.83 over the past year. Analyst firm CIBC maintained a "Neutral" rating but increased the price target to C$56.00, reflecting optimism about the company's long-term gro...
Cintas Corporation posted robust first-quarter results, surpassing analyst expectations with earnings per share of $1.39 and revenue of $3.01 billion, a 10.9% increase year-over-year. The company's organic revenue growth was 8.9%, reflecting solid bu...
Oppenheimer lowered Nike's price target to $52 from a higher level, reflecting concerns over falling sales and macroeconomic challenges. Despite Nike's stock trading near its 52-week low around $35.35, the new target implies a potential 44.85% upside...
